Get the latest tech news
Miist, founded by a 25-year-old, wants people to vape their way out of smoking addiction and migraines
As a university student, Dalton Signor was troubled by how many people around him smoked or vaped, including his grandmother and 14-year-old sister.
Signor (pictured center) felt that existing smoking cessation medicines, whether patches, gums, or lozenges, are not very effective because they take too long to start working. But when Signor presented him with the results of the company’s Phase I trial, the former Andreessen Horowitz partner who helped launch that firm’s first Bio Fund, instantly changed his mind. Signor explained that Miist’s technology produces particles that are 50% smaller than other inhalers, which means the medicine is deposited deeper in the lungs, where the lining is just one cell thick, leading to faster absorption into the bloodstream.
Or read this on TechCrunch
